Eli Lilly and Company : Trend support as stepping stone
By Oscar Salza
Entry price | Target | Stop-loss | Potential |
---|---|---|---|
$42.34 | $0 | $41.6 | -100% |
The company is correctly valued with a price earnings ratio of 12x, against average sector of 16x. According to Surperformance trading ratings, the group has strong fundamentals, both in terms of business predictability and valuation.
Following a bullish wave, the stock now shows a slight decline that should lead towards its USD 41.47 medium-term support. On this level, remobilization of buyer flows would allow an uptrend in the medium and long term. Investors could take a buy order on this level and get a good entry point with a first target price of USD 44.5 and a stop below the medium term support.